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Oogenesis) have emerged as important subcellular structures that are involved in mRNA
metabolism. To date, a detailed description of P-bodies in Drosophila oogenesis is lacking. To this end, we ﬁrst
demonstrate that Drosophila decapping protein 2 (dDcp2) contains intrinsic decapping activity and its
enzymatic activity was not detectably enhanced by Drosophila decapping protein 1 (dDcp1). dDcp1-
containing bodies in the nurse cell cytoplasm can associate with the 5′ to 3′ exoribonuclease, Pacman in
addition to dDcp2 and Me31B. The size and number of dDcp1 bodies are dynamic and dramatically increased
in dDcp2 and pacman mutant backgrounds supporting the conclusion that dDcp1 bodies in nurse cell
cytoplasm are Drosophila P-bodies. In stage 2–6 oocytes, dDcp1 bodies appear to be distinct from previously
characterized P-bodies since they are insensitive to cycloheximide and RNase A treatments. Curiously, dDcp2
and Pacman do not colocalize with dDcp1 at the posterior end of the oocyte in stage 9–10 oocytes. This
suggests that dDcp1 bodies are in a developmentally distinct state separate from the 5′ end mRNA
degradation enzymes at later stages in the oocyte. Interestingly, re-formation of maternally expressed dDcp1
with dDcp2 and Pacmanwas observed in early embryogenesis. With respect to developmental switching, the
maternal dDcp1 is proposed to serve as a marker for the re-formation of P-bodies in early embryos. This also
suggests that a regulated conversion occurs between maternal RNA granules and P-bodies from oogenesis to
embryogenesis.
© 2008 Elsevier Inc. All rights reserved.IntroductionTight regulation of gene expression is critical for the success of
developmental processes. Recently, the role of messenger RNA
degradation has emerged as an important step in the regulation of
gene expression (reviewed in Garneau et al., 2007). The impairment of
the 5′ to 3′mRNAdegradationpathway can result in detrimental effects.
In Caenorhabditis elegans, dual knock down of decapping protein 1 (dcp1)
and decapping protein 2 (dcp2) by RNAi can result in partial embryonic
lethality (Lall et al., 2005). In Drosophila, the early embryonic develop-
ment is arrested in dDcp1 mutant backgrounds (Lin et al., 2006). In
Arabidopsis, cell differentiation is arrested at postembryonic growth in
dcp1 and dcp2 mutants (Xu et al., 2006). Further, the knockdown of C.
elegans 5′ to 3′ exoribonuclease xrn-1 can result in embryos that fail to
complete ventral enclosure (Newbury and Woollard, 2004). Therefore,
the 5′ to 3′mRNA degradation pathway plays important roles in various
developmental processes among species.
In the 5′ to 3′mRNA degradation pathway, the 3′ poly(A) tail of the
polyadenylated mRNA is usually removed by the deadenylase enzymehi University, No. 701, Sec. 3,
wan.
l rights reserved.complex. After deadenylation, the 5′ cap structure is decapped and the
mRNA body is subsequently digested in the 5′ to 3′ direction (reviewed
in Parker and Song, 2004). The cleavage of the 5′ cap structure
represents a critical step in mRNA degradation and turnover. In yeast,
the Dcp1p decapping enzyme is a critical mediator of mRNA decay and
an essential component of the 5′ to 3′mRNAdecay pathway (reviewed
in Parker and Song, 2004). The two conserved eukaryotic decapping
proteins, Dcp1 and Dcp2, function together as a holoenzyme to cleave
the 5′ cap structure with Dcp2 being the catalytic subunit. Many of the
proteins involved in the 5′ to 3′ mRNA degradation pathways are
enriched in cytoplasmic foci termed Processing bodies (P-bodies).
Proteins found in P-bodies include the Dcp1 and Dcp2 proteins,
stimulators of decapping including Dhh1, Edc3, and Hedls/Ge-1 (also
referred to as Edc4), the Lsm1-7 complex, and the 5′ to 3′
exoribonuclease Xrn1 (reviewed in Eulalio et al., 2007a; Fillman and
Lykke-Andersen, 2005; Newbury et al., 2006; Parker and Sheth, 2007).
In yeast, evidence suggests that P-bodies can be sites of bothmRNA
decay and storage becausemRNAs have also been shown to re-emerge
from P-bodies into polysomes (Brengues et al., 2005). Recently, several
additional RNA granules have been described including maternal
mRNA granules and neuronal granules which share many funda-
mental components with P-bodies. For example, the Drosophila polar
granule, neuronal granule, and P-body share dDcp1 and Me31B, a
Drosophila homolog of Dhh1p, as common components (Barbee et al.,
Fig. 1. Recombinant dDcp1 does not contain intrinsic decapping activity and does not
stimulate recombinant dDcp2 decapping. Four pmol of His-tagged recombinant wild-
type proteins dDcp1, dDcp2, and mutants dDcp1R57A/G172D, dDcp2E133/4Q were tested for
their ability to hydrolyze cap-labeled RNA in a standard in vitro decapping assay as
described in Materials and methods. Recombinant proteins were incubated with 32P-
cap-labeled pcP RNA at 37 °C for 30 min. Wild-type dDcp1 and double mutant
dDcp1R57A/G172D do not contain decapping activity (lanes 2 and 3). Wild-type dDcp2
carries intrinsic decapping activity (lane 4) as the human decapping enzyme hDcp2
(lane 6). In contrast, double mutant dDcp2E133/4Q lost decapping activity (lane 5). His-
tagged αCP1 was used as a negative control (lane 7). Recombinant dDcp2 decapping
activity (lane 9) was not increased by adding His-tagged dDcp1 (lanes 10–12). A
schematic representation of the 32P-cap-labeled pcP RNA substrate is shown on the
bottom where the line represents the RNA body, the m7Gppp denotes the cap and the
asterisk indicates the position of the 32P.
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protein implicated in intracellular RNA transport, is a common
component of the Drosophila polar granule and neuronal granule
(Barbee et al., 2006). The presence of common components among
different RNA granules implies that the interchange of components
between different RNA granules might be possible.
In Drosophila S2 culture cells, decapping proteins together with
several effectors of mRNA degradation components are found to be
colocalized in cytoplasmic P-bodies (Eulalio et al., 2007b). However, a
detailed description of P-bodies in Drosophila oogenesis and a
biochemical analysis of the decapping proteins are lacking. To
characterize the properties of the Drosophila P-body in oogenesis, we
ﬁrst showed that dDcp2 contains intrinsic decapping activity by in
vitro decapping assays and it colocalizes with dDcp1, Pacman, and
Me31B in nurse cell cytoplasm. Similar to previously characterized P-
bodies in yeast, Drosophila S2 culture cells, and mammalian cells,
dDcp1-containing foci (dDcp1 bodies)were sensitive to cycloheximide
and RNase A treatment in nurse cell cytoplasm. Together with the fact
that the size and number of dDcp1 bodies are affected in dDcp1, dDcp2,
and pacman mutant backgrounds, we conclude that dDcp1 bodies in
nurse cell cytoplasm represent Drosophila P-bodies. In addition, we
found that P-bodies are responsive to heat stress and exist in a dynamic
state in the cytoplasm of nurse cells. Surprisingly, dDcp1 bodies in the
oocytes were distinct from previously characterized P-bodies yet
acquire the full complement of P-body components upon deposition of
maternal dDcp1 in early stage embryos suggesting that a developmen-
tally regulated conversion occurs betweenmaternal RNA granules and
P-bodies during the oogenesis to embryogenesis transition.
Results
dDcp2 contains intrinsic decapping activity
DrosophilamelanogasterDcp1 (dDcp1) is found tobe required for the
proper degradation of several maternal mRNAs in early embryogenesis
(Lin et al., 2006). dDcp1, dDcp2 and Me31B have been shown to
colocalize within discrete cytoplasmic foci in Drosophila nurse cells
(Barbee et al., 2006; Lin et al., 2006), and S2 culture cells (Eulalio et al.,
2007b). In addition, these three proteins are present in P-bodies and are
involved inmRNAdecapping (Coller and Parker, 2004),withDcp2being
the catalytic subunit (Van Dijk et al., 2002; Wang et al., 2002; Lykke-
Anderson, 2002; Steiger et al., 2003). We therefore reasoned that these
foci constitute Drosophila P-bodies and set out to biochemically
determine the decapping properties of dDcp1 and dDcp2.
Four different forms ofDrosophila Dcp2 transcripts at the dDcp2 locus
are reported in FlyBase (FlyBase ID, FBgn0036534 and Fig. S1A). The
coding sequences of dDcp2-B and dDcp2-D transcripts are identical.
dDcp2-A and dDcp2-C isoforms contain long N-terminal extensions
which are unique in Dcp2 variants among species. Through themultiple
sequence alignment, dDcp2-B/D is found to be most orthologous to its
human and yeast homologs and contains a conserved Nudix hydrolase
motif which is required for Dcp2 decapping activity in the yeast and
human proteins (Van Dijk et al., 2002; Wang et al., 2002; Lykke-
Anderson, 2002; Steiger et al., 2003) (Fig. S1B). To test whether dDcp1
and dDcp2 have intrinsic decapping activity, in vitro decapping assays
were performed using His-tagged dDcp1 and His-tagged dDcp2 B-form
proteins. In the decapping assays, wild-type His-tagged dDcp1 and
double mutated His-tagged dDcp1R57A/G172D contained comparable and
background levels of decapping activity indicating that dDcp1 does not
contain intrinsic decapping activity (Fig.1, lanes 2 and 3) under the assay
conditions employed. However, the possibility that the His-tag might
have a negative effect on dDcp1 decapping activity cannot be excluded.
The background activity detected is likely due to copurifying contam-
inating bacterial protein that can hydrolyze the cap (Liu et al., 2008, in
press). In dDcp1R57A/G172D which converts arginine 57 to alanine and
glycine 172 to aspartic acid, the two mutated amino acids are conservedamong species and disrupt the ability of Dcp1p to stimulate decapping in
yeast (Tharun and Parker, 1999). The lack of decapping activity of dDcp1
is consistent with yeast Dcp1p and human Dcp1a which also lack
intrinsic decappingactivity (Lykke-Anderson, 2002;VanDijk et al., 2002;
Steiger et al., 2003). In contrast to dDcp1, dDcp2 contains robust
decapping activity comparable to that observedwith humanDcp2 (Fig.1,
lanes 4 and 6). To conﬁrm that the observed decapping activity is a
function of dDcp2, two conserved glutamates that are critical for Dcp2
decapping in other organisms (Dunckley and Parker, 1999; Lykke-
Andersen, 2002;VanDijk et al., 2002;Wanget al., 2002)weremutated to
glutamines at amino acids 133 and 134 (dDcp2E133/4Q). As expected, only
background levels of decapping activity, were detected with the
dDcp2E133/4Q dual mutation (Fig. 1, lane 5).
Although the yeast Dcp1p protein does not contain intrinsic
decapping activity, it is essential for decapping and serves to stimulate
Dcp2-mediate decapping enzymatic activity in yeast (She et al. 2004;
Steiger et al., 2003). However, a similar stimulatory function has not
been observed with human Dcp1 (Lykke-Andersen, 2002; Van Dijk et
al., 2002). The discrepancy in the properties of Dcp1 in different
species indicates that the mechanism of Dcp2 decapping regulation
may be different among species. We therefore tested whether dDcp1
can enhance the decapping activity of dDcp2. Our results indicate that
dDcp1 alone cannot enhance dDcp2 decapping activity in an in vitro
decapping assay. The decapping activity of recombinant dDcp2 (Fig. 1,
lane 9) did not increase upon addition of an increasing titration of His-
tagged dDcp1 protein (Fig. 1, lanes 9–12). Collectively, the above data
indicate that dDcp2 encodes a decapping enzyme with intrinsic
decapping activity and similar to human Dcp1a, dDcp1 does not
detectably stimulate decapping in the absence of other proteins.
Pacman is localized in discrete cytoplasmic foci in nurse cell
P-bodies are sites of mRNA degradation and contain several mRNA
degradation factors including the 5′ to 3′ exoribonuclease, Xrn1
278 M.-D. Lin et al. / Developmental Biology 322 (2008) 276–288(reviewed in Fillman and Lykke-Andersen, 2005). Xrn1 degrades the
mRNAbodyonlyafter the 5′ cap structure is removed (Decker andParker,
1993; Hsu and Stevens, 1993). Xrn1 is localized to P-bodies (reviewed in
Eulalio et al., 2007a; Fillman and Lykke-Andersen, 2005; Parker and
Sheth, 2007) and the size and number of P-bodies dramatically increase
in an xrn1mutant background (Cougot et al., 2004; Eulalio et al., 2007b).
This phenomenon can be explained by the accumulation of decapped
mRNA and is coincident with the exoribonuclease activity of Xrn1.
Although punctuate Pacman distribution in stage 8 nurse cell
cytoplasm has been reported (Barbee et al., 2006), a detailed
cytoplasmic distribution of Pacman during oogenesis has not yet
been carefully examined. We therefore set out to determine the
distribution of the Drosophila homolog of Xrn1, Pacman (Chernukhin
et al., 2001; Till et al., 1998), during oogenesis. Pacman forms discrete
cytoplasmic foci in nurse cells from stage 2 to stage 7 (Figs. 2A–C). At
stage 9, Pacman becomes ubiquitously distributed throughout the
entire nurse cell cytoplasm and only a few ﬁne dots of Pacman bodies
can be observed (Fig. 2D). Both the temporal and spatial distribution of
the punctate staining pattern of Pacman in nurse cell cytoplasm is
very similar to that of dDcp1 and dDcp2 (Lin et al., 2006). However,
unlike dDcp2, Pacman is not localized in nurse cell nuclei (Figs. 2A–D).Fig. 2. Pacman localizes within discrete foci in nurse cell cytoplasm. (A–D) Pacman antibo
chambers. (A–C) In nurse cells, Pacman can be detected in punctate particles in the cytoplasm
the posterior end. (D) In nurse cells, Pacman signals are greatly reduced in the cytoplasm.
reproduced at the bottom (A and B) or at the right (C and D) as enlarged views of the sameIn the oocyte, Pacman is restricted to the posterior end before stage 7
(Figs. 2A–C). After stage 9, the Pacman staining in the oocyte is very
faint and unclear (Fig. 2D). In summary, a developmentally dynamic
distribution of Pacman can be observed in different stages (from stage
2 to stage 9) of oogenesis.
As a crucial component of the 5′ to 3′mRNA degradation pathway,
we propose that the punctate Pacman bodies in nurse cell cytoplasm
are most likely Drosophila P-bodies. However, the possibility that the
Pacman bodies in the nurse cell cytoplasm are simply storage sites for
Pacman proteins cannot be excluded. Further, the lack of Pacman (Fig.
2D) and dDcp2 (Lin et al., 2006) staining in the oocyte after stage 9
indicates that the posterior localized dDcp1 in the oocyte may not
function as foci for mRNA degradation since they lack detectable levels
of the two critical nuclease in 5′ to 3′mRNA decay and could represent
a novel form of P-bodies.
dDcp1 is colocalized with dDcp2, Me31B, and Pacman but not Tazman in
nurse cell cytoplasm
In yeast and human tissue culture cells, Dcp1 has been considered
as a marker for P-bodies (Cougot et al., 2004; Sheth and Parker, 2003;dy staining in wild-type (A) stage 2 and 3, (B) stage 5, (C) stage 7 and (D) stage 9 egg
. In the oocyte of early stage egg chambers, Pacman particles are more concentrated in
In the oocyte, Pacman cannot be clearly detected. In each panel, the indicated inset is
ﬁeld. Arrows indicate Pacman foci in the nurse cell cytoplasm.
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Dcp1 is able to colocalize with Dcp2, Dhh1, Edc3, the Lsm1-7 complex,
and the 5′ to 3′ exoribonuclease Xrn1 (reviewed in Eulalio et al.,
2007a). In Drosophila, dDcp1 colocalizes with both dDcp2 (Lin et al.,
2006) and Me31B (Barbee et al., 2006; Lin et al., 2006) in nurse cell
cytoplasm and somatic S2 culture cells (Eulalio et al., 2007b). Also, the
colocalization between Me31B and Pacman in nurse cell cytoplasm
has also been reported (Barbee et al., 2006). To extend the previousFig. 3. dDcp1 colocalizes with dDcp2, Pacman, andMe31B but not Tazman in nurse cell cytopl
cell cytoplasm. (C) Merged image. (D–F) YFP-dDcp1 (green) (D) is colocalized with (E) Pacma
(G) is colocalized with (H) dDcp2 (red) in the stage 7 nurse cell cytoplasm. (I) Merged image.
cytoplasm. (L) Merged image. (M–O) YFP-dDcp1 (green) (M) does not colocalize with (N) T
localized in nurse cell nucleus. (O) Merged image. In each panel, the indicated inset is reprod
2 μm.studies and further examine whether dDcp1 is an authentic P-body
marker in oogenesis, we examined its possible colocalization with
other canonical P-body components.
If dDcp1 marks P-bodies which are involved in mRNA degrada-
tion, then they would be expected to include the Drosophila 5′ to 3′
exoribonuclease, Pacman (Chernukhin et al., 2001; Till et al., 1998).
To determine the colocalization between Pacman and dDcp1 in
nurse cell cytoplasm, stage 6–7 egg chambers expressing YFP-dDcp1asm. (A–C) YFP-dDcp1 (green) (A) is colocalized with (B) dDcp2 (red) in the stage 7 nurse
n (red) in the stage 7 nurse cell cytoplasm. (F) Merged image. (G–I) GFP-Me31B (green)
(J–L) GFP-Me31B (green) (J) is colocalized with (K) Pacman (red) in the stage 7 nurse cell
azman (red) in stage 6 egg chambers. The majority of the Tazman staining signals are
uced at the lower right as enlarged views of the same ﬁeld. The scale bar in each inset:
280 M.-D. Lin et al. / Developmental Biology 322 (2008) 276–288were immunostained with antibodies against either dDcp2 or
Pacman. As previously described (Lin et al., 2006), YFP-dDcp1 can
colocalize with dDcp2 in the nurse cell cytoplasm (Figs. 3A–C). We
also showed that Pacman (Fig. 3E) can colocalize with YFP-dDcp1
(Figs. 3D–F) in nurse cell cytoplasm as well as in the oocyte. To check
whether Pacman is also able to colocalize with Me31B, egg chambers
expressing GFP-Me31B were examined. The results showed that
GFP-Me31B (Fig. 3G) is colocalized with dDcp2 (Fig. 3H). Fig. 3,
panels J–L show that Pacman is colocalized with GFP-Me31B (Fig. 3J)
in nurse cell cytoplasm as well as the oocyte. Together with the fact
that dDcp1 is colocalized with Me31B (Barbee et al., 2006; Lin et al.,
2006) and both are colocalized with dDcp2 (Figs. 3A–C and G–I,
respectively), we conclude that dDcp1, dDcp2, Me31B, and Pacman
are colocalized in particles which resemble P-bodies in the nurse cell
cytoplasm. In addition, in stage 7 egg chambers, Pacman is also
colocalized with dDcp1 in the ooplasm, albeit at lower levels than
dDcp1 and dDcp2.
In yeast, components of the 3′ to 5′mRNAdegradation pathway are
absent from P-bodies suggesting that mRNA 3′ end decay does not
occur in these foci. For instance, the key exosome subunit Ski7p, which
is required for 3′ to 5′mRNA degradation, does not localize in P-bodies
(Sheth and Parker, 2003). To assess whether the Drosophila 3′ to 5′
mRNA degradation components are able to localize in P-bodies, we
examined the Tazman localization in egg chambers expressing YFP-Fig. 4. Most of dDcp1 bodies do not colocalize with Ccr4 in both nurse cells and cellular bla
dDcp1 (red) in the stage 6 nurse cell cytoplasm of the nanos-Gal4VP16";;";UAS-HA-ccr4 egg c
dDcp1 (arrow). Note that the oocyte is not included in this optical section. (C) Merged image
(D–F) The majority of GFP-dDcp1 bodies (green) (D) are colocalized with (E) dDcp2 bodies
parents. (F) Merged image. Arrows indicate GFP-dDcp1 bodies that are perfectly colocalized
(H) Ccr4 (red) bodies in the cellular blastoderm embryos. The embryoswere produced by GFP
partially colocalized with Ccr4 bodies. Arrowhead indicates distinct Ccr4 body that does nodDcp1. Tazman is the Drosophila homolog of the yeast exosome
component Rrp44p which is required for 3′ to 5′ mRNA degradation
(Cairrao et al., 2005). In egg chamber expressing YFP-dDcp1, Tazman is
mainly localized in the nurse cell nucleus (Fig. 3N) and does not
colocalize with dDcp1 (Fig. 3M). Furthermore, only trace amount of
Tazman can be observed in the oocyte. This result implies that 3′ to 5′
mRNA degradation most likely does not occur in Drosophila P-bodies
within nurse cell cytoplasm.
Most dDcp1 bodies do not overlap with Ccr4 in the nurse cells and
cellular blastoderm embryo
Exonucleolytic removal of the poly(A) tail is the ﬁrst step in mRNA
decay and appears to be the rate-limiting and regulated step in many
cases examined (reviewed in de Moor et al., 2005). In yeast, the major
deadenylase complex contains Ccr4p as the catalytic subunit (Chen et
al., 2002; Tucker et al., 2001; Tucker et al., 2002). Although the
deadenylase complexes have been extensively studied, the location for
deadenylation in the cytoplasm is still not very clear. It has been
suggested that Ccr4p can transiently localize to the foci containing
decapping factors or is present in foci of its own in yeast (Sheth and
Parker, 2003). In human cells, hCcr4 is colocalized with cytoplasmic
foci enriched in hDcp1a (Cougot et al., 2004). This suggests that the
human deadenylation process may also occur in P-bodies.stoderm embryos. (A–C) Most of HA-Ccr4 (green) bodies (A) do not colocalize with (B)
hambers, while a very limited number of HA-Ccr4 bodies are partially colocalized with
. Arrowhead indicates distinct HA-Ccr4 body that does not colocalize with dDcp1 body.
(red) in the cellular blastoderm embryos. The embryos were produced by GFP-dDcp1
with dDcp2 bodies. (G–I) Most of GFP-dDcp1 bodies (green) (G) are not colocalized with
-dDcp1 parents. (I) Merged image. Arrows indicate that only a fewGFP-dDcp1 bodies are
t colocalize with dDcp1 body.
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reside with the Ccr4-Not complex which has been found to
concentrate in discrete cytoplasmic foci although it is not clear
whether these foci are P-bodies (Temme et al., 2004). Moreover,
Smaug, a translational repressor, is found to be partially colocalized
with Ccr4 and dDcp1 in syncytial blastoderm embryos (Zaessinger et
al., 2006). This observation implies the association of Ccr4 and dDcp1
bodies in the cytoplasm of syncytial blastoderm embryo. Since the
colocalization between Ccr4 and dDcp1 bodies has not yet been
clariﬁed, we stained dDcp1 in HA-Ccr4 expressing egg chambers to
exam whether Drosophila Ccr4 can colocalize with dDcp1 in nurseFig. 5. Depletion of mRNA decay factors affects the size and number of Drosophila P-bodies in
The direct observation of YFP-dDcp1 in a stage 6, pcm5/FM7a; YFP-dDcp1/CyO egg chamber.
of YFP-dDcp1 in a stage 6, pcm5/JA27; YFP-dDcp1/CyO egg chamber. pcm5/JA27; YFP-dDcp1/C
egg chambers. (C) Antibody staining of dDcp2 in a stage 6, pcm5/FM7a egg chamber. pcm5/FM
egg chambers. pcm5/pcm5 females are cultivated in 18 °C. (E, F) Pacman bodies are increased
egg chamber. (F) Antibody staining of Pacman in a stage 6, dDcp1442P/dDcp1442P; T2R57A/MKR
Antibody staining of dDcp1 in a stage 6, wild-type egg chamber. (H) Antibody staining of dcells. In nanos-Gal4 driven HA-Ccr4 egg chambers, the majority of HA-
Ccr4 bodies in nurse cell cytoplasm are not colocalized with dDcp1
(arrowhead in Figs. 4A–C). In contrast to humanDcp1awhich is able to
colocalize with hCcr4 in culture cells (Cougot et al., 2004), dDcp1
displays a very limited colocalization proﬁle with Ccr4 in the
cytoplasm of nurse cells (arrow in Figs. 4A–C; 6 partially overlapped
foci out of 48 distinct dDcp1 foci). Therefore we tested whether dDcp1
bodies can colocalize with Ccr4 bodies in embryonic cells. As a control,
the localization of dDcp2 bodies in GFP-dDcp1 expressing embryos
was examined. In cellular blastoderm embryos, most of the GFP-
dDcp1 bodies (arrows in Fig. 4D) are colocalized with dDcp2 bodiesnurse cells. (A, B) YFP-dDcp1 bodies are increased in pacmanmutant egg chambers. (A)
pcm5/FM7a; YFP-dDcp1/CyO females were cultivated in 18 °C. (B) The direct observation
yO females were cultivated in 18 °C. (C, D) dDcp2 bodies are increased in pacmanmutant
7a females are cultivated in 18 °C. (D) Antibody staining of dDcp2 in a stage 6, pcm5/pcm5
in dDcp1mutant egg chambers. (E) Antibody staining of Pacman in a stage 6, wild-type
S egg chamber. (G, H) dDcp1 bodies are increased in dDcp2 mutant egg chambers. (G)
Dcp1 in a stage 6, dDcp2de21 GLC egg chamber.
282 M.-D. Lin et al. / Developmental Biology 322 (2008) 276–288(arrows in Fig. 4E; 12 overlapped foci out of 22 dDcp2 distinct foci).
These dDcp1–dDcp2 colocalized foci hence could represent P-bodies
in embryonic cells. In contrast, the majority of GFP-dDcp1 bodies
(arrowhead in Fig. 4G) do not colocalize with Ccr4 bodies (arrowhead
in Fig. 4H). Similar to observations in nurse cells, only a few Ccr4
bodies are intimately associated with dDcp1 bodies (arrows in Fig. 4C;
5 overlapped foci out of 51 distinct Ccr4 foci). Collectively, our data
demonstrate that a small subset of foci containing Ccr4 colocalizes
with P-bodies while the majority of Drosophila Ccr4 cytoplasmic foci
are not associated with P-bodies and might be sites of deadenylation
or Ccr4 protein storage.
Depletion of mRNA decay factors affects the size and number of P-bodies
in nurse cells
The above data suggests that the dDcp1 bodies in the cytoplasm of
nurse cells are analogous to P-bodies. Further conﬁrmation of this
premise was provided by an alteration of P-body number and size
upon disruption of factors involved in mRNA decapping or exoribo-
nuclease activity. Depletion of decapping proteins or the exoribonu-
clease Xrn1 results in the accumulation of mRNA processing
intermediates leading to a dramatic increase in P-body number and
size (Sheth and Parker 2003; Cougot et al., 2004). Two pacmanmutant
alleles, the pacman3(pcm3) and pacman5(pcm5), were generated by
excision of a P-element insertion downstream of the pacman gene,
between it and the neighboring gene CG12202. Western blotting
experiments show that pcm5 homozygous females produce an
undetectable amount of full length Pacman protein, whereas pcm3
mutants express low levels of truncated protein (Fig. S2B). Fig. S2A
shows that pacman mutant females produce lower number of eggs
than isogenic controls, with the fertility of the pcm5 homozygotes
being only 7.1% of that of the isogenic controls. Examination of mutant
egg chambers showed that they appeared normal up to stage 8/9 but
then rapidly degenerate (Fig. S2C). We have shown that a null
mutation in dDcp1 (dDcp1442P) caused very low fertility in GLC
females and most of the egg chambers are arrested by stage 6 (Lin et
al., 2006). Therefore, as for dDcp1, down-regulation of Pacman protein
in egg chambers can result in substantial lowering of fertility showing
that this exoribonuclease is required for proper oogenesis.
pcm5 is a cold sensitive pacman mutant allele. When pcm5 is in
combination with JA27, which is a deletion line that covers the pac-
man locus, and reared in 18 °C, the Pacmanprotein expression is barely
detected (Fig. S2). Therefore, the ovaries from 18 °C reared pcm5/FM7a;
YFP-dDcp1/CyO and pcm5/JA27; YFP-dDcp1/CyO females were exam-
ined for the YFP-dDcp1 expression. In the nurse cell cytoplasm, the
average size and number of YFP-dDcp1 bodies in pcm5/JA27 egg
chamber (Fig. 5B) is increased to ∼180% and ∼145% of that in pcm5/
FM7a heterozygous control egg chamber (Fig. 5A), respectively. This
result indicates that dDcp1 bodies are sensitive to the status of mRNA
degradation. Since dDcp2 is able to colocalize with dDcp1 (Figs. 3A–C),
we also expect an increase of the size of dDcp2 bodies in pacman
mutant background. Again, we tested this possibility in pcm5/FM7a
and pcm5/pcm5 females that reared in 18 °C. As expected, both the
average size and number of dDcp2 bodies increased to ∼200% in pcm5
homozygous mutant egg chambers (Fig. 5D) comparing to the pcm5/
FM7a heterozygous control (Fig. 5C).
The above data indicate that the size of both dDcp1 and dDcp2
bodies increases in response to a pacman mutant. Inversely, Pacman
bodies should also increase when the process of mRNA decapping is
defective. Our previous studies indicate that dDcp1R57A protein
produced in the T2R57A transgene was impaired in its mRNA
degradation function (Lin et al., 2006). To create a stock in which
the dDcp1 decapping function is impaired, we introduced the T2R57A
transgene into dDcp1 null background (dDcp1442P). In dDcp1442P/
dDcp1442P; T2R57A/MKRS egg chambers (Fig. 5F), Pacman bodies in the
nurse cell cytoplasm are increased to ∼2.6 times the average size ofthe wild-type control egg chambers (Fig. 5E). We also examined the
dDcp1 distribution in dDcp2de21 null background which contains a
6315 bp deletion covering the entire dDcp2 coding region (Chen, et. al.,
unpublished). Therefore in the absence of dDcp2 protein, decapping
should not occur in the dDcp2 null mutation and we expect an
increase of dDcp1 bodies as a consequence of the accumulation of
deadenylated mRNAs. As expected, the average size of dDcp1 bodies is
∼6 times increased in dDcp2de21 nurse cell cytoplasm (Fig. 5H)
compared towild-type egg control chambers (Fig. 5G). In contrast, the
levels of dDcp1 and dDcp2 in the oocyte do not change appreciably,
suggesting that these oocyte particles do not behave in the same way
as yeast and human P-bodies.
Overall, these results show that the dDcp1/dDcp2/Pacman parti-
cles in the nurse cell cytoplasm are dynamic structures and the
depletion of mRNA decay factors can increase their size and number,
strongly suggesting that they are functionally P-bodies.
YFP-dDcp1 bodies are sensitive to cycloheximide and RNase A treatments
Translational inhibitors such as cycloheximide are known to
stabilize mRNAs (reviewed in Jacobson and Peltz, 1996) and inhibit
translation elongation by trapping mRNA on polysomes. If structures
enriched inmRNAdecay factors are actively involved in degradation of
mRNAs, we expect their disappearance or reduction after cyclohex-
imide treatment since most of the cellular mRNAs would be trapped
within polysomes. In contrast, if they represent the storage sites of
mRNA decay factors, we should observe an increase in the size and
number after cycloheximide treatment due to the accumulation of
unused decay factors. The number and size of P-bodies are reduced
after cycloheximide treatment in yeast,Drosophila S2, andmammalian
cells, suggesting the particles are actively involved in mRNA decay
(Cougot et al., 2004; Sheth and Parker, 2003; Eulalio et al., 2007b).
To test whether dDcp1 bodies in ovaries can respond to
cycloheximide treatment, hand-dissected ovaries expressing YFP-
dDcp1 were treated with 10 μg/ml cycloheximide for 30 min. In the
nurse cell cytoplasm of cycloheximide treated egg chambers, we
observed a substantial reduction of the average size (60% reduction)
and number (40% reduction) of YFP-dDcp1 bodies (Fig. 6B) compared
to the DMSO treated control (Fig. 6A). However, the YFP-dDcp1 signals
in the oocyte cytoplasm were not reduced signiﬁcantly (Fig. 6B). To
rule out the possibility that the decrease of YFP-dDcp1 bodies was not
a consequence of reduced YFP-dDcp1 protein levels, western blot
analysis was used to demonstrate that YFP-dDcp1 was stable for at
least 1 h following cycloheximide treatment (data not shown). To rule
out the possibility that the cycloheximide treatment disrupted the
polarity and organization of the oocyte and resulted in a indirect effect
on the behavior of YFP-dDcp1 bodies, a posterior localized oskar
reporter, osk-(ms2)6 (Supplementary materials and methods) was
used to examine the polarity of oocytes after cycloheximide
treatment. Our results indicate that the cycloheximide treatment
does not affect the posterior localization of the osk-(ms2)6 reporter in
ovaries co-expressing osk-(ms2)6 and MCP-GFP (Fig. S3). Therefore,
the reduction of YFP-dDcp1 bodies after cycloheximide treatments
was not caused by an indirect effect. In summary, these results
strongly suggest that the dDcp1-containing bodies in nurse cell
cytoplasm do not appear to be exclusively protein storage sites for
mRNA decay factors. Rather, they are eithermRNP storage sites or sites
of mRNA decay.
Previous studies in both budding yeast, Drosophila S2, and human
cells indicate that RNA is required for P-body assembly (Eulalio et al.,
2007b; Sen and Blau, 2005; Teixeira et al., 2005). To examine whether
RNA is also required for the assembly of the dDcp1 bodies in egg
chambers, hand-dissected egg chambers expressing YFP-dDcp1 were
treated with RNase A and the YFP emission was directly examined by
confocal microscopy. A signiﬁcant reduction in YFP-dDcp1 bodies was
detected in nurse cells with a corresponding increase in diffuse
Fig. 6. dDcp1 cytoplasmic foci are sensitive to both cycloheximide and RNase A treatments (A, B) YFP-dDcp1 bodies are greatly reduced after cycloheximide treatment. Hand-
dissected YFP-dDcp1 ovaries were treated with either (A) DMSO solvent or (B) 10 μg/ml cycloheximide in DMSO for 30 min. After two washes with PBS, the treated ovaries were
directly observed for YFP emission under confocal microscope. (B) The cycloheximide treatment causes the reduction of YFP-dDcp1 particles in nurse cell cytoplasm. Note that the
YFP-dDcp1 bodies in the oocyte are not reduced. (C, D) YFP-dDcp1 bodies are not detected following RNase A treatment. Hand-dissected YFP-dDcp1 egg chambers were
permeabilized in lysis buffer for 50 s and washed twice with PBS. Egg chambers were then incubated with either PBS only (C) or PBS containing 300 μg/ml RNase A (D) for 5 min. Egg
chambers were washed twice in PBS and then directly examined by confocal microscope. The YFP-dDcp1 bodies are no longer detectable and the YFP-dDcp1 proteins are evenly
distributed throughout the nurse cell cytoplasm in (D) RNase A treated egg chamber compared with (C) the untreated control egg chamber.
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(Fig. 6D) while distinctive YFP-dDcp1 bodies were still detected in the
PBS treated control (Fig. 6C). These data suggest that the YFP-dDcp1
bodies in nurse cells are RNase sensitive and dependent on RNA forFig. 7. The amount of YFP-dDcp1 bodies responds to heat-shock treatment. (A) Direct dete
increased in heat-shocked egg chambers. Females expressing YFP-dDcp1 were heat-shocked
180 min at 25 °C before dissection. (F) After recovery for 240 min at 25 °C, the amount of YF
heat-shock treatment.their integrity. In contrast, strong YFP-dDcp1 signal was still detected
in the oocyte (Fig. 6D). These data indicate that the dDcp1 bodies in
the oocyte are resistant to RNase treatment and their integrity is
independent of RNA. They further suggest that dDcp1 bodies inction of YFP-dDcp1 egg chambers at 25 °C. (B–E) YFP-dDcp1 bodies are dramatically
in 37 °C for 1 h and allowed to recover for (B) 5 min, (C) 60 min, (D) 120 min, and (E)
P-dDcp1 bodies reverted back to the condition similar to that in egg chambers without
Fig. 8. A small subset of GFP-Stau cytoplasmic particles is able to colocalize with dDcp1
in nurse cells. (A–C) Large GFP-Stau (green) particles surround nurse cell nuclei. Small
GFP-Stau particles (arrows) are distributed in the nurse cell cytoplasm. Few (A) GFP-
Stau particles in the nurse cell cytoplasm (arrows) are able to colocalize with (B) dDcp1
(red) in the stage 7 egg chamber. (C) Merged image. However, in the oocyte
(arrowhead), GFP-Stau and dDcp1 are completely colocalized. In each panel, the
indicated inset is reproduced at the lower right as enlarged views of the same ﬁeld.
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cells. Taken together with the results of cycloheximide and RNase A
treatment indicate that the dDcp1 bodies in the nurse cell cytoplasm
are Drosophila P-bodies with properties similar to yeast, Drosophila
S2, and human P-bodies.
YFP-dDcp1 bodies are dramatically increased in response to heat stress
P-bodies in budding yeast can respond to several different kinds of
stress. For example, the size and number of P-bodies increase in
response to glucose deprivation, osmotic stress, and ultraviolet light
exposure (Teixeira et al., 2005). Although heat stress has not been
reported to lead to an increase in the sizeor numbersof P-bodies inyeast
(Teixeira et al., 2005), the heat stress used was relatively mild (37 °C) so
may not have been strong enough to elicit a P-body response (Bond,
2006). In human DU145 cells, exposure to heat-shock (44 °C for 1 h) can
result in an increase in the number of P-bodies (Kedersha et al., 2005).
To test the link between heat stress and dDcp1 body number in
Drosophila, we used YFP-dDcp1 as a marker for Drosophila P-bodies in
nurse cells to examine the possible response to heat stress. The YFP-
dDcp1 females were heat-shocked for 1 h at 37 °C and allowed to
recover for varies time points at 25 °C prior to dissection of their ovaries
and detection of YFP emission. After 5 min of heat-shock, YFP-dDcp1
foci were dramatically increased and closely associated with nurse cell
nuclei (Fig. 7B) compared with the non-heat-shocked control (Fig. 7A).
The accumulation of YFP-dDcp1 bodies can still be detected 180 min
after heat-shock (Figs. 7B–E). By 240 min following heat-shock, the
number and size of YFP-dDcp1 bodies reverted to the status similar to
that of untreated control egg chambers (Fig. 7F). The area fraction of
aggregated YFP-dDcp1 bodies in nurse cells increased to 8.7% after
5 min of heat-shock (Fig. 7B) from 0.7% of non-heat-shocked control
(Fig. 7A). By 240 min following heat-shock, the area fraction of
aggregated YFP-dDcp1 bodies in nurse cells is down to 1.6% (Fig. 7F)
which is similar to non-heat-shocked control. These results indicate that
Drosophila P-bodies can respond to heat stress and these effects are
reversible (Figs. 7A–F). In contrast, dDcp1 staining in the oocyte did not
change appreciably after heat stress. These data conﬁrm that dDcp1
particles in the nurse cell cytoplasm are akin to P-bodies in human cells
whereas the accumulation of dDcp1 in the oocyte represents a particle
distinct from P-bodies.
dDcp1 colocalizes with GFP-Staufen in the oocyte, while colocalization in
the nurse cells is limited
Staufen (Stau) which contains double-stranded RNA-binding
domains has been shown to be present in mammalian stress granules,
neuronal granules (Thomas et al., 2005), and P-bodies in culture cells
(reviewed in Anderson and Kedersha, 2006). In Drosophila, Stau is
found to reside in neuronal granules related to somatic P-bodies
(Barbee et al., 2006) and P-bodies of S2 culture cells (Eulalio et al.,
2007b). However, the relationship between Stau and dDcp1 in
oogenesis has not been established. Stau is found to be associated
with maternal mRNAs including osk and responsible for the posterior
transportation of osk in the oocyte (Ramos et al., 2000; St Johnston et
al., 1991). In addition to be a component of P-body, dDcp1 is also a
component of osk mRNP complex (Lin et al., 2006). Other P-body
components, Exu and Me31B which colocalize with dDcp1 in nurse
cells (Lin et al., 2006 and Figs. 3J–L, respectively) are also components
of an oskmRNP complex (Nakamura et al., 2001;Wilhelm et al., 2000).
The presence of shared components between the osk mRNP complex
and P-bodies raises the possibility that certain interactions between
these two cytoplasmic RNA granules might exist in nurse cells.
To test whether Stau-containing mRNP complexes are able to
interact with dDcp1-containing P-bodies in nurse cells, we examined
the possible association and/or colocalization between Stau and
dDcp1 in GFP-Stau expressing egg chambers. Large GFP-Stau particlessurrounding the nurse cell nuclei together with smaller particles
throughout the cytoplasm were observed in nurse cells (Fig. 8A).
Through the dual staining of anti-GFP and anti-dDcp1 antibodies, we
found that a small subset of GFP-Stau particles in the nurse cell
cytoplasm is able to colocalize with dDcp1 particles (arrows in insets
of Figs. 8A–C; 9 overlapped foci out of 35 distinct GFP-Stau foci).
Although in a small subset, the colocalization between GFP-Stau and
dDcp1 raise the possibility that a dynamic transit of shared
components from P-body to Stau-containing mRNP in nurse cell
cytoplasm might occur. In addition, in the oocyte cytoplasm (arrow-
head), GFP-Stau and dDcp1 are completely colocalized. This again
implies that the dDcp1 complexes in the oocyte are functionally
distinct from those in the nurse cell cytoplasm.
Maternally expressed dDcp1 is able to reform P-bodies with dDcp2 and
Pacman in early embryogenesis
Maternal-expressed dDcp1 is necessary for the proper degradation
of several maternal mRNAs including osk, bicoid, and twine during
maternal-zygotic transition in early embryogenesis since the removal
of dDcp1 causes delayed mRNA degradation (Lin et al., 2006).
Although dDcp1 is able to colocalize with dDcp2 (Lin et al., 2006
and Figs. 3A–C) and Pacman (Figs. 3D–F) in the stage 2–6 nurse cell
cytoplasm, both dDcp2 (Lin et al., 2006) and Pacman (Fig. 2D) are not
localized to the posterior pole of the oocyte after stage 9. Furthermore,
by using a posterior localized osk-(ms2)6 reporter, we also demon-
strate that dDcp1 is able to colocalize with osk-(ms2)6 in the posterior
Fig. 9. Maternally expressed GFP-dDcp1 colocalize with dDcp2 and Pacman in early embryogenesis. (A–C) Early stage embryos laid by GFP-dDcp1 females. (A) An early syncytial
blastoderm embryo. The maternally expressed GFP-dDcp1 is localized at the posterior end of the embryo. Scale bar: 20 μm. (B) An early cellular blastoderm embryo. Scale bar: 10 μm.
(C) A cellular blastoderm embryo. The maternal GFP-dDcp1 (arrowhead) was redistributed in the cytosol of cellularized cells. In addition, GFP-dDcp1 is also localized in the cytoplasm
of pole cells (arrow). Green: anti-GFP, scale bar: 20 μm. (D–F) A cellular blastoderm embryo laid by GFP-dDcp1 females. (D) Maternally expressed GFP-dDcp1 is colocalized with (E)
dDcp2 in the cytoplasm of cellular blastoderm embryos (arrows). Arrowsmark two clear GFP-dDcp1 bodies that are colocalized with dDcp2. (F) Merged images. Green: anti-GFP, red:
anti-dDcp2, scale bar: 16 μm. (G–I) A cellular blastoderm embryo laid by GFP-dDcp1 females. (G) Maternally expressed GFP-dDcp1 is colocalized with (H) Pacman in the cytoplasm of
cellular blastoderm embryos (arrow). Arrow marks one of the GFP-dDcp1 bodies that colocalized with Pacman. (I) Merged images. Green: anti-GFP, red: anti-Pacman, scale bar:
15.64 μm.
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S4). The lack of colocalization among dDcp1, dDcp2, and Pacman in the
oocyte, suggested to us that the maternally deposited dDcp1 in the
mature egg might be recruited into P-bodies in early embryogenesis
for maternal mRNA degradation. To evaluate this possibility, embryos
obtained from females carrying a maternal-speciﬁc GFP-dDcp1
transgene were examined. The maternal α4 tubulin promoter driven
GFP-dDcp1 ensures that GFP-dDcp1 observed in early embryos is
derived from the oocyte but not from the zygotic dDcp1 expression. In
early syncytial blastoderm embryo, GFP-dDcp1 is localized at the
apical region of the embryo (Fig. 9A). During cellularization, GFP-
dDcp1 is concentrated at the apical pole of the elongated nuclei (Fig.
9B) which corresponds to the position of themicrotubule organization
center (Callaini and Anselmi, 1988; Kellogg et al., 1991). In the cellular
blastoderm embryo, GFP-dDcp1 is redistributed and forms discrete
cytoplasmic foci (Fig. 9C) throughout the cellularized cells. Impor-
tantly, the timing of the formation of these discrete GFP-dDcp1
cytoplasmic foci is coincident with that for maternal mRNAs
degradation including osk, bicoid, and twine (Lin et al., 2006). Wetherefore speculate that the maternal GFP-dDcp1 bodies observed in
cellular blastoderm embryos are P-bodies. To further substantiate this
possibility, embryos expressing maternal GFP-dDcp1 were dual
stained with either anti-GFP and anti-dDcp2 antibodies or anti-GFP
and anti-Pacman antibodies. As expected, the maternal GFP-dDcp1
bodies in the cellular blastoderm embryos can colocalize with dDcp2
(Figs. 9D–F) and Pacman (Figs. 9G–I). Collectively with our previous
observations (Lin et al., 2006) and the correlation of the timing of P-
body re-formation and maternal mRNA degradation, we propose that
the maternally produced dDcp1 in the egg might be recruited into P-
bodies and contribute to the degradation of a certain subset of
maternal mRNAs in early embryogenesis.
Discussion
dDcp2 intrinsic decapping activity and its relationship with dDcp1
To gain a clearer understandingof thedevelopmental expression and
function of the dDcp1 and dDcp2 decapping proteins, we tested their
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throughout Drosophila oogenesis and early embryogenesis.
We ﬁrst demonstrated that the Drosophila Dcp2 protein possesses
intrinsic decapping activity using in vitro decapping assays (Fig. 1).
Consistent with both yeast and human Dcp1 proteins, intrinsic
decapping activity was not detected for dDcp1 (Fig. 1). Previous
studies from yeast indicate that Dcp1p can enhance the decapping
activity of Dcp2p (Beelman et al., 1996; Steiger et al., 2003) possibly by
promoting or stabilizing a catalytically active conformation of Dcp2p
(She et al. 2008). However, we did not detect a stimulation of dDcp2
decapping at least in vitro (Fig. 1) despite their colocalization in the
nurse cell cytoplasm (Figs. 3A–C). One possibility for the lack of
stimulation could be that additional proteins might be required for a
stable interaction between dDcp1 and dDcp2. Human Dcp2 decapping
is stimulated by theHedls/Ge-1 protein (Fenger-Gron et al., 2005; Yu et
al., 2005). Hedls/Ge-1, which contains an N-terminal WD40 motif and
C-terminal domains characterized by a repeating ψ(C2–3) motif,
promotes the association between Dcp1a and hDcp2 and is proposed
to facilitate hDcp2 decapping (Fenger-Gron et al., 2005; Yu et al., 2005).
A likely possibility remains that the Drosophila homolog of Hedls/Ge-1
(CG6181) or a functionally equivalent protein, that was absent in the in
vitro assays, might be necessary to facilitate an interaction between
dDcp2 and dDcp1 and thereby stimulate dDcp2 decapping.
P-bodies might be sites of mRNP assembly
Consistentwith dDcp1bodies in S2 culture cells (Eulalio et al., 2007b),
our data presented here indicate that dDcp1 bodies in the nurse cell
cytoplasm can represent P-bodies in oogenesis. Studies indicate that
activators ofmRNAdecapping such as yeast Dhh1p andmammalianRCK/
p54 have been found to be translational repressors (Coller and Parker,
2005). These ﬁndings led to amodel inwhich the translational status of a
cytoplasmic mRNA is the consequence of competition between the
translational apparatus and the repression apparatus (Coller and Parker,
2005). Furthermore, a reciprocal movement of mRNAs between
polysomes and P-bodies is possible (Brengues et al., 2005). Therefore, a
dynamic switch of mRNAs among translational activation, translational
repression, and degradation is conceivable. In this study, we demon-
strated that dDcp1 bodies can partially colocalize with GFP-Stau in nurse
cell cytoplasm (Fig. 8). Together with the fact that Stau is a double-
stranded RNA-binding protein (Ramos et al., 2000) and a common
component of RNA granules including stress granule, neuronal granule
and somatic P-body inmammalian andDrosophila S2 cells (Anderson and
Kedersha, 2006; Barbee et al., 2006; Eulalio et al., 2007b; Kedersha et al.,
2005), it is possible that P-bodies in the nurse cell cytoplasm could be
sites of Stau-containing maternal mRNP assembly.
dDcp1 bodies in the oocyte appear to be modiﬁed P-bodies
In the oocyte, accumulation of Pacman at the posterior pole is
especially obvious in stage 2–6 egg chambers (Figs. 2A, B and3K). In
addition, strong dDcp1, dDcp2, andMe31B signals can be detected at the
posterior pole of the oocyte in similar stages (Fig. 3). Considering the
inactive biological nature and maternal mRNA deposition and storage
functions of oocyte, the requirement for the mRNA degradation in the
oocyte is assumed to be very limited. If this is the case, the accumulated
dDcp1, dDcp2, Me31B, and Pacman in the oocyte before stage 6may not
function as foci for mRNA degradation. One possibility is that Me31B
which colocalizewith dDcp1 bodies in stage 2–6 oocytes (Lin et al., 2006
and Figs. 3A–L) contributes to formation of a translationally repressed
complex. In Drosophila, Me31B is involved in translational repression of
maternal mRNAs (Nakamura et al., 2001) through the interaction with
eIF4E, Cup, and Bruno (Nakamura et al., 2004; Wilhelm et al., 2003). In
addition, Me31B can participate with an FMRP-associated translational
repression function in developing eye imaginal discs and in bantam
miRNA-mediated translational repression inwing imaginal discs (Barbeeet al., 2006). Therefore, it is possible that the posterior accumulated
mRNA decay factors in stage 2–6 oocyte may represent translational
repressed complexes and function to store maternal mRNAs. This
hypothesis is further supported by the fact that yeast P-bodies can
function as storage sites for translationally repressed mRNAs (Brengues
et al., 2005). Our observations that the YFP-dDcp1 signals in stage 6
oocyte are insensitive to cycloheximide (Fig. 6B), RNase A treatment (Fig.
6D) and heat-shock (Fig. 7) also support this hypothesis. Following stage
9, dDcp1 is localized to the posterior end of the oocyte (Lin et al., 2006
and Figs. S4A–C) and colocalized with Stau (Lin et al., 2006). In contrast,
both dDcp2 (Lin et al., 2006 and Figs. S4D–F) and Pacman (Fig. 2D and
Figs. S4G–I) are not localized to the posterior pole of the oocyte after
stage 9. This argues that the posterior localized dDcp1 bodies in the
oocyte most likely do not function as foci for mRNA degradation since
they lack the 5′ to 3′ mRNA degradation enzymes, dDcp2 and Pacman.
In conclusion, our data raises the intriguing possibility that dDcp1
may function in translational repression and/or on maternal RNA
granule storage in stage 2–6 oocyte. It also suggests that, in Drosophila
oocyte after stage 9, dDcp1 is not an appropriate marker to represent
canonical P-bodies involved in mRNA degradation. Further, the
posterior localized dDcp1 bodies in the oocyte could be considered
as a novel form of modiﬁed P-bodies ready for its conversion into
zygotic P-bodies in early embryogenesis (see below).
The possible developmental conversion between dDcp1-containing
maternal RNA granule and zygotic P-body
In stage 9–10 oocyte, dDcp1 does not colocalize with dDcp2 and
Pacman (Lin et al., 2006; and Fig. 2) while they reunite again in early
embryogenesis (Fig. 9). These results suggest that there is a dDcp1
independent function of dDcp2 and Pacman in oogenesis and a
sophisticated regulation of mRNA degradation during Drosophila
oogenesis. The timing of the re-formation of P-bodies in the early
embryo coincides with the degradation of maternal mRNAs during
maternal-zygotic transition. Further, the degradation of bicoid, osk,
and twine mRNAs during maternal-zygotic transition in early
embryogenesis is dependent on dDcp1 activity (Lin et al., 2006).
Considering dDcp1 is a component of osk mRNP, we suspect that a
direct conversion from the dDcp1-containing maternal RNA granules
to the zygotic P-body in early embryogenesis may be responsible for
the efﬁcient and dramatic degradation of maternal mRNAs at 2–3 h
AEL (stage 14) (Lin et al., 2006). This proposal is supported by the fact
that shared mRNA decay components in addition to dDcp1 are found
in both maternal RNA granules and P-bodies. For example, Me31B is a
component of the osk mRNP complex in the oocyte (Nakamura et al.,
2001) and its counterpart, Dhh1p/Rck, resides in yeast and human P-
bodies (Sheth and Parker, 2003; Cougot et al., 2004).
Collectively, ourdata indicate aﬂuctuationof P-bodynumberandsize
from oogenesis to embryogenesis. In the nurse cell cytoplasm, the
colocalization among dDcp1 and other mRNA decay components
including dDcp2 and Pacman in the stage 6–7 nurse cells (Fig. 3) implies
the presence of P-bodies with mRNA degradation function, although
theirmRNAstorage function cannotbe excluded. In theoocyte after stage
9, dDcp1 (Figs. S4A–C and Lin et al., 2006) and Me31B (Nakamura et al.,
2001) are able to localize to the posterior pole of oocyte. In contrast,
dDcp2 and Pacman which contain the major degradation enzyme
activities do not localize to the posterior pole of the stage 9 oocyte (Figs.
S4D–I and 2D and Lin et al., 2006). This suggests that accumulation of
dDcp1 in the oocyte at late stages is in a developmental state without
mRNA degradation function. In early embryogenesis, we observed the
colocalization of maternally expressed dDcp1 with dDcp2 (Figs. 9D–F),
and Pacman (Figs. 9G–I). This re-formation of maternally produced
dDcp1with dDcp2 and Pacman indicates the re-formation of P-bodies in
early embryogenesis, which might be responsible for the abrupt
degradation of certain maternal mRNAs at the cellularization stage
mediated by dDcp1 (Lin et al., 2006). This dynamic change and
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mRNA turnover during development.
Drosophila P-bodies can response to heat stress
In Fig. 7, we show that heat stress induces a clump of P-body
aggregation around nurse cell nuclei. Moreover, this aggregation can be
reversed (Figs. 7A–F). Morphologically, this dynamic nature resembles
the behavior of mammalian stress granules that function to store
translationally stalled housekeeping mRNAs in stress conditions
(reviewed in Anderson and Kedersha, 2002; Kedersha and Anderson,
2002). We therefore suspect the aggregation of P-bodies around nurse
cell nuclei under heat stressmight be functionally related tomammalian
stress granules in certainway. One possibility is that theseDrosophila P-
bodies in the nurse cell cytoplasm can be a functional homolog of
mammalian stress granules. Another possibility is that distinct stress
granules co-existwithP-bodies and cooperatewithP-bodies in response
to stress conditions. Till now, the functional homologs of mammalian
stress granules have not yet been identiﬁed inDrosophila. To distinguish
these two alternatives, it is critical to identify the existence ofDrosophila
homologs of mammalian stress granule components.
Materials and methods
Drosophila stocks
Oregon R (OR) is used as the wild-type strain. Fly stocks were
raised at 25 °C on standard cornmeal medium. The following
transgenic stocks were used in this study: P{w+; GFP-Me31B}
(Nakamura et al., 2001), P{w+; UASp-HA-ccr4} (Semotok et al.,
2005), P{w+; YFP-dDcp1} (Lin et al., 2006), P{w+; mat-tub-alpha4:
GFP-dDcp1} (this line contains a GFP-dDcp1 transgene driven from the
maternal α4 tubulin promoter), P{w+; mat-tub-alpha4:GFP-Staufen}
(Schuldt et al., 1998), and nanos-Gal4VP16 (Van Doren et al., 1998). For
pacmanmutants, stock 11456 (obtained from Bloomington Drosophila
Stock Center) carrying the P insertion P{EP}EP1526 was used to create
pcm3 and pcm5by imprecise P-element excision using standard
protocols. These mutants were further characterized at the molecular
level by ampliﬁcation of DNA at either side of the breakpoint using
primers jes1 5′-TCCCGATCACGATGAAGACC-3′ and big1 5′-
ACTGCCGCCTCAGATCTG-3′. Full details on the generation of pacman
mutant alleles are given elsewhere (Grima et al., 2008).
Fertility experiments
Flies homozygous for pcm5 or pcm3were mated towild-type males
(OregonR) and number of eggs counted over 10 h at 25 °C. Egg
chambers were visualised by dissecting females in Ringers solution
ﬁxing egg chambers (Verheyen, E. and Cooley, L. (1994) “Looking at
oogenesis” Methods Cell Biol. vol 44 545–561.), staining with DAPI
(1 μg/ml for 5 min) and mounting in 70% glycerol.
In vitro decapping assays
In vitro decapping assays were carried out using 32P-cap-labeled
pcP RNA with the indicated protein as previously described (Wang et
al., 2002). The decapping products were resolved by polyethylenei-
mine (PEI) cellulose thin-layer chromatography (TLC) developed in
0.75 M LiCl. TLC plates were exposed to PhosphorImager. The full
length coding sequences of HA-tagged dDcp1 and dDcp2 were
subcloned form EST clone GH04763 or EST clone SD14939 respectively
into the pRest vectors. The mutant plasmids pRSET-dDcp1R57A/G172D
and pRSET-dDcp2E133/4Q were generated by site-directed mutagenesis
using QuikChange multi site-directed mutagenesis kit (Strategene)
according to the manufacturer's manual. All plasmids were conﬁrmed
by sequencing. His-tagged proteins were expressed in Escherichia coliand puriﬁed with His Bind Resin according to the manufacturer's
manual (Novagen; San Diego, CA).
Immunoﬂuorescence staining and image analysis
Ovaries from 1- to 3-day old females were dissected in PBS on ice
and ﬁxed for 20 min in ﬁxative (600 μl of heptane, 200 μl of 2%
paraformaldehyde in PBS, and 1 μl of NP-40). After 3 washes with PBT
(PBS plus 0.2% Tween 20), the ﬁxed ovaries were incubated in PBT
containing 1% Triton X-100 for 1 h. Ovaries were then blocked for 3 to
5 h in 5% normal goat serum in PBT, and incubated overnight at 4 °C in
primary antibody diluted in PBT (1:200 for rabbit anti-Ccr4 antibody
(Temme et al., 2004); 1:20 for rabbit anti-dDcp1 antibody; 1:100 for
rabbit anti-dDcp2 antibody; 1:500 for rabbit anti-Pacman antibody;
1:50 for rabbit anti-Tazman antibody (Cairrao et al., 2005); 1:100 for
chicken anti-GFP antibody; 1:100 for rat anti-HA antibody). The
ovaries were then washed 3 times for 20 min each in PBT, and then
incubated for 2 h at room temperature in secondary antibody in PBT.
Following three 30 min washes in PBT, the ovaries were mounted in
anti-fade mounting solution (PBS containing 50% glycerol and 2%
DABCO). For preparation of an antibody to Pacman, a cDNA encoding a
54 kDa C-terminal portion of Pacman was expressed as a His-tag
fusion protein in E. coli using the expression vector pET28a. The
histidine tag was removed by thrombin treatment and the pacman
protein fragment cut from the gel for use in raising antibodies. The
antibody was prepared by the company Eurogentec.
The image analysis was performed by using the software ImageJ
which is a public domain Java image processing program developed by
Wayne Rasband (http://rsb.info.nih.gov/ij/index.html). The distinct
particles were analyzed by using the “Analyze particles” command of
ImageJ. The colocalization of cytoplasmic foci was analyzed by the
“Colocalization” plug-in that developed by Pierre Bourdoncle.
RNase A and cycloheximide treatment of dissected egg chambers
For RNase A treatment, hand-dissected egg chambers that are
expressing EYFP-dDcp1 were permeabilized in lysis buffer (100 mM
potassium phosphate, pH 7.8, with 0.2% Triton X-100) for 50 s and
washed twice with PBS. Egg chambers were then incubated with either
PBSor PBS containingRNaseA (300 μg/ml) for 5min. Eggchamberswere
washed twice in PBS and then directly examined by confocal micro-
scopy. For cycloheximide treatment, hand-dissected egg chambers
expressing EYFP-dDcp1 were incubated in Schneider's Drosophila
medium (GIBCO) containing 10 μg/ml of cycloheximide for 30 min.
Egg chambers were thenwashed with PBS twice and directly examined
by confocal microscope.
Heat-shock of YFP-dDcp1 ﬂies
We incubated well-fed female ﬂies expressing EYFP-dDcp1 in 37 °C
for 1 h. After heat-shock, female ﬂies were recovered in 25 °C for
15 min. The ovaries were then dissected for direct observation of
EYFP-dDcp1 by confocal microscopy.
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